vs
Side-by-side financial comparison of BlackSky Technology Inc. (BKSY) and RHYTHM PHARMACEUTICALS, INC. (RYTM). Click either name above to swap in a different company.
RHYTHM PHARMACEUTICALS, INC. is the larger business by last-quarter revenue ($57.3M vs $35.2M, roughly 1.6× BlackSky Technology Inc.). BlackSky Technology Inc. runs the higher net margin — -2.5% vs -83.0%, a 80.5% gap on every dollar of revenue. On growth, RHYTHM PHARMACEUTICALS, INC. posted the faster year-over-year revenue change (36.9% vs 15.9%). Over the past eight quarters, RHYTHM PHARMACEUTICALS, INC.'s revenue compounded faster (48.5% CAGR vs 20.5%).
BlackSky Technology Inc. is a leading geospatial intelligence provider operating a constellation of high-revisit small Earth observation satellites. It delivers real-time satellite imagery, advanced data analytics, and dynamic monitoring solutions to government, defense, critical infrastructure, and commercial clients globally to support data-driven operational decision-making.
Rhythm Pharmaceuticals is a biopharmaceutical firm focused on developing and commercializing targeted therapies for rare genetic disorders causing severe unmanageable obesity, including POMC deficiency, LEPR deficiency, and Bardet-Biedl syndrome. It serves patients in North America and Europe who lack effective standard treatments for their chronic life-altering conditions.
BKSY vs RYTM — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $35.2M | $57.3M |
| Net Profit | $-868.0K | $-47.5M |
| Gross Margin | — | 91.6% |
| Operating Margin | -11.8% | -82.2% |
| Net Margin | -2.5% | -83.0% |
| Revenue YoY | 15.9% | 36.9% |
| Net Profit YoY | 95.5% | -9.6% |
| EPS (diluted) | $0.04 | $-0.73 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $35.2M | $57.3M | ||
| Q3 25 | $19.6M | $51.3M | ||
| Q2 25 | $22.2M | $48.5M | ||
| Q1 25 | $29.5M | $32.7M | ||
| Q4 24 | $30.4M | $41.8M | ||
| Q3 24 | $22.5M | $33.3M | ||
| Q2 24 | $24.9M | $29.1M | ||
| Q1 24 | $24.2M | $26.0M |
| Q4 25 | $-868.0K | $-47.5M | ||
| Q3 25 | $-15.3M | $-52.9M | ||
| Q2 25 | $-41.2M | $-46.6M | ||
| Q1 25 | $-12.8M | $-49.5M | ||
| Q4 24 | $-19.4M | $-43.3M | ||
| Q3 24 | $-12.6M | $-43.6M | ||
| Q2 24 | $-9.4M | $-32.3M | ||
| Q1 24 | $-15.8M | $-141.4M |
| Q4 25 | — | 91.6% | ||
| Q3 25 | — | 89.3% | ||
| Q2 25 | — | 88.6% | ||
| Q1 25 | — | 88.8% | ||
| Q4 24 | — | 90.9% | ||
| Q3 24 | — | 88.5% | ||
| Q2 24 | — | 89.9% | ||
| Q1 24 | — | 89.2% |
| Q4 25 | -11.8% | -82.2% | ||
| Q3 25 | -85.8% | -102.6% | ||
| Q2 25 | -62.8% | -93.4% | ||
| Q1 25 | -40.5% | -143.7% | ||
| Q4 24 | -20.0% | -98.6% | ||
| Q3 24 | -58.7% | -132.0% | ||
| Q2 24 | -47.0% | -139.2% | ||
| Q1 24 | -54.7% | -538.7% |
| Q4 25 | -2.5% | -83.0% | ||
| Q3 25 | -78.2% | -103.1% | ||
| Q2 25 | -185.8% | -96.1% | ||
| Q1 25 | -43.4% | -151.4% | ||
| Q4 24 | -63.9% | -103.6% | ||
| Q3 24 | -55.8% | -131.2% | ||
| Q2 24 | -37.7% | -110.9% | ||
| Q1 24 | -65.2% | -544.4% |
| Q4 25 | $0.04 | $-0.73 | ||
| Q3 25 | $-0.44 | $-0.82 | ||
| Q2 25 | $-1.27 | $-0.75 | ||
| Q1 25 | $-0.42 | $-0.81 | ||
| Q4 24 | $-0.61 | $-0.71 | ||
| Q3 24 | $-0.66 | $-0.73 | ||
| Q2 24 | $-0.52 | $-0.55 | ||
| Q1 24 | $-0.88 | $-2.35 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $124.5M | $388.9M |
| Total DebtLower is stronger | $201.1M | — |
| Stockholders' EquityBook value | $94.9M | $139.1M |
| Total Assets | $386.2M | $480.2M |
| Debt / EquityLower = less leverage | 2.12× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $124.5M | $388.9M | ||
| Q3 25 | $146.5M | $416.1M | ||
| Q2 25 | $93.8M | $291.0M | ||
| Q1 25 | $75.8M | $314.5M | ||
| Q4 24 | $52.5M | $320.6M | ||
| Q3 24 | $63.2M | $298.4M | ||
| Q2 24 | $41.2M | $319.1M | ||
| Q1 24 | $35.4M | $201.2M |
| Q4 25 | $201.1M | — | ||
| Q3 25 | $195.1M | — | ||
| Q2 25 | $122.5M | — | ||
| Q1 25 | $115.3M | — | ||
| Q4 24 | $107.7M | — | ||
| Q3 24 | $98.8M | — | ||
| Q2 24 | $108.6M | — | ||
| Q1 24 | $85.0M | — |
| Q4 25 | $94.9M | $139.1M | ||
| Q3 25 | $91.1M | $148.8M | ||
| Q2 25 | $86.6M | $-11.9M | ||
| Q1 25 | $88.8M | $18.9M | ||
| Q4 24 | $94.0M | $21.7M | ||
| Q3 24 | $110.3M | $11.2M | ||
| Q2 24 | $76.5M | $39.3M | ||
| Q1 24 | $81.7M | $61.6M |
| Q4 25 | $386.2M | $480.2M | ||
| Q3 25 | $380.9M | $506.9M | ||
| Q2 25 | $310.8M | $372.7M | ||
| Q1 25 | $284.9M | $386.7M | ||
| Q4 24 | $254.1M | $392.3M | ||
| Q3 24 | $245.5M | $363.6M | ||
| Q2 24 | $224.3M | $381.8M | ||
| Q1 24 | $210.1M | $258.7M |
| Q4 25 | 2.12× | — | ||
| Q3 25 | 2.14× | — | ||
| Q2 25 | 1.41× | — | ||
| Q1 25 | 1.30× | — | ||
| Q4 24 | 1.15× | — | ||
| Q3 24 | 0.90× | — | ||
| Q2 24 | 1.42× | — | ||
| Q1 24 | 1.04× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-9.3M | $-25.4M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-9.3M | $-25.4M | ||
| Q3 25 | $-39.0M | $-26.6M | ||
| Q2 25 | $-7.3M | $-23.3M | ||
| Q1 25 | $27.2M | $-40.4M | ||
| Q4 24 | $-1.8M | $-18.8M | ||
| Q3 24 | $1.0M | $-25.2M | ||
| Q2 24 | $-1.8M | $-29.1M | ||
| Q1 24 | $-3.8M | $-40.7M |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
